 |
Hiroaki
Mitsuya [NCGM / Kumamoto University] |
Opening Remarks | |
| Session
I |
9:10-10:25 〔75〕 | ||
| Chairs: Hiroaki Mitsuya & Shuzo Matsushita | |||
 |
O-1-01 |
Robert
Murphy Northwestern University, USA |
Progress in HIV Therapy |
 |
O-1-02 |
Hiroaki
Mitsuya NCGM / Kumamoto University, Japan |
Structure-guided development of molecular-targeting antiviral agents for treatment of HIV infection and AIDS |
| 10:25-10:40
〔15〕 |
Coffee Break | ||
| Session
II |
10:40-12:10 〔90〕 | ||
| Chairs: Shinich Oka & Wataru Sugiura | |||
 |
O-1-03 |
Wataru
Sugiura NMC / GSK, Japan |
Molecular epidemiology of acquired and transmitted drug resistant HIV in Japan |
 |
O-1-04 |
Takeshi
Nishijima NCGM, Japan |
Management of chronic kidney diseases in HIV-1-infected patients in the era of “treatment for all” strategy |
 |
O-1-05 |
Yorifumi
Satou Kumamoto University, Japan |
Clonality of HIV-1-infected cells in PBMCs of HIV-1-infected individuals |
| 12:10-13:30
〔80〕 |
Lunch | ||
| Session
III |
13:30-14:30 〔60〕 | ||
| Chairs: Seiji Okada & Shinya Suzu | |||
 |
O-1-06 |
Takeo
Kuwata Kumamoto University, Japan |
Impact of gp41 mutations for escape from a broad neutralizing antibody against SIV |
 |
O-1-07 |
Takamasa
Ueno Kumamoto University, Japan |
Relative resistance of HLA-B to down-regulation by naturally-occurring HIV-1 Nef sequences |
| Session
IV |
14:30-15:45 〔75〕 | ||
| Chairs: Tetsuro Matano & Takamasa Ueno | |||
 |
O-1-08 |
Takuya
Yamamoto NIBIO / Kumamoto University, Japan |
CD150 signal modulation enhances SHIV-specific TFH cell responses |
 |
O-1-09 |
Rebecca
Lynch NIAID, NIH, USA |
Impact of broadly neutralizing antibody VRC01 on HIV-1 after infusion into chronically infected subjects |
| 15:45-16:00
〔15〕 |
Coffee Break | ||
| Session
V |
16:00-16:45 〔45〕 | ||
| Chair: Masafumi Takiguchi | |||
 |
O-1-10 |
Victor
Appay INSERM, France |
CD8+ T cell efficacy and preservation of immune resources in HIV infection |
| Session
VI |
16:45-17:30 〔45〕 | ||
| Chair: Shuzo Matsushita | |||
 |
O-1-11 |
Dan H.
Barouch Harvard Medical, USA |
Novel HIV Vaccine and Eradication Strategies |